U.S. License Holder:
Coherus Biosciences / Formycon / Bioeq
Date of License:
August-02-2022 (Interchangeable)
Last Update:
August-15-2022
FDA-Approved Indications
CIMERLI (ranibizumab-eqrn), a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with:
Neovascular (Wet) Age-Related Macular Degeneration (AMD);
Macular Edema Following Retinal Vein Occlusion (RVO);
Diabetic Macular Edema (DME);
Diabetic Retinopathy (DR);
Myopic Choroidal Neovascularization (mCNV).